Achiko AG (XSWX:ACHI) Current Accrued Expense : CHF0.00 Mil (As of Jun. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Achiko AG Current Accrued Expense?

Achiko AG's Current Accrued Expense for the quarter that ended in Jun. 2022 was CHF0.00 Mil.

Achiko AG Current Accrued Expense Historical Data

The historical data trend for Achiko AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG Current Accrued Expense Chart

Achiko AG Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Current Accrued Expense

Achiko AG Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Current Accrued Expense	Get a 7-Day Free Trial			-	-	-	-	-

Achiko AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Achiko AG Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Achiko AG's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Achiko AG (XSWX:ACHI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

Tessinerplatz 7, Zurich, CHE, CH-8002

Website

https://www.achiko.com

Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines